Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

s, the conduct and results of future clinical trials, plans regarding regulatory filings, future research, discovery of new product candidates, and clinical trials, and plans regarding partnering and outlicensing activities and the participation at upcoming scientific conferences. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in larger- scale or later clinical trials, the risk that the Company will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, the risks associated with reliance on collaborative partners for future revenues under the terms of its existing collaboration agreements, the risks associated with further clinical trials, development and commercialization of product candidates, and the risks associated with recruiting and retention of individuals in key management functions. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed in Micromet's periodic reports and other filings with the SEC, including the "Risk Factors" sections of such reports.

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Micromet, Inc.


'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Sept. 1, 2015 The American Brain Tumor ... for its Discovery Research Grant program. LOIs are due ... noon CDT. Discovery Grants are one-year, $50,000 ... potential to change current diagnostic or treatment paradigms for ... encourage novel research at its earliest stages, in the ...
(Date:9/1/2015)... YORK , Sept. 1, 2015 /PRNewswire-USNewswire/ ... of cancer death in American men. One ... cancer and 233,000 new cases are diagnosed annually. ... experts are using a powerful new technique, ... small and large cancer lesions, treating only the ...
(Date:9/1/2015)... ... 2015 , ... In her thought provoking debut novel ‘ Ebola Vaccine Wars ... faced with an Ebola pandemic that is on the cusp of wiping out humanity. ... world of counterterrorism, and who continues to appear in this series of books by ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... , Equine cervical facet joint problems can be caused by injuries and ... cause impingement of nerve roots or of the spinal cord itself. This can ...
Breaking Biology Technology:American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3
... Incorporated,(Nasdaq: SPEX ) reported a net loss for the three months ended March 31,2008 ... on the company,s on-going Phase 3 clinical trial,in the use of Naturlose for the treatment ... million and reflected the,start-up costs for the trial., , ... ...
... their 2008 Annual,Meeting, shareholders of Spherix Incorporated (Nasdaq: SPEX ) ... Douglas T. Brown, Senior VP and Manager of Corporate Banking Government ... Cox, Jr., Principal, Asset Protection Company -- Claire L. Kruger, ... Spherix -- Gilbert V. Levin, Ph.D., Director of Science and ...
... Executive Chairman Set Sights on Expanding,Therapeutic Horizons of ... BOSTON, SAN DIEGO, SAN FRANCISCO and SEATTLE, May ... joined Fate Therapeutics as,president and CEO and executive ... internationally recognized stem cell scientists,clinicians and investors dedicated ...
Cached Biology Technology:Spherix Reports 1st Quarter Earnings 2Spherix Holds Annual Shareholders Meeting 2Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 2Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 3Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 4Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 5Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 6
(Date:9/1/2015)... MOUNTAIN VIEW, Calif. , Sept. 1, 2015 ... interaction with travelers during airport passenger screening. This ... which the passenger screening process will become unintrusive. ... and pre-clearance based on voluntary background investigations will ... analysis from Frost & Sullivan, Global Airport ...
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 ... systems, announced today it will unveil its "Guardian S" ... at the National Tactical Officers Association Conference on August ... Guardian S is the first-ever commercially available energetically autonomous ... research and in-field trials and is protected by more ...
(Date:8/20/2015)... CT ., Aug. 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces it has joined The Smart Card Alliance and ... Smart Card Alliance and the Smart Card Alliance Latin ... visibility to industry peers and thought leaders promoting adoption ...
Breaking Biology News(10 mins):The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 2The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 4Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4
... biosensor microchip that could significantly speed up the ... highly sensitive "nanosensors," analyze how proteins bind to ... effectiveness and possible side effects of a potential ... nanosensors can simultaneously and continuously monitor thousands of ...
... oil spill caused social disruption and psychological stress among ... the Exxon Valdez spill and the impacts are likely ... "Just ask the residents of Cordova today whether they ... Ritchie, assistant director for research of the University of ...
... study by researchers at the Virginia Institute of Marine ... does kill large numbers of copepodstiny crustaceans that are ... studyby VIMS graduate student Samantha Bickel, VIMS professor Kam ... the March issue of the Journal of Experimental ...
Cached Biology News:New biosensor microchip could speed up drug development, Stanford researchers say 2New biosensor microchip could speed up drug development, Stanford researchers say 3Gulf oil spill similar to Exxon Valdez in initial social and mental impacts, study finds 2VIMS study: Propeller turbulence may affect marine food webs 2VIMS study: Propeller turbulence may affect marine food webs 3
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... Low Speed Shaker ,Product Information ... shaker is a high quality, general purpose shaker ... after the other models in the line, the ... easy-access control panel. Electronic controls are utilized for ...
... a chromogenic medium for the detection, ... (except S. thyphi) and total coliforms ... takes a maximum of 24 hours, ... sterilization during preparation and performs a ...
... ActiveSight, the leading provider of X-ray ... offers fragment-based screening services to its ... involves the binding of drug-like fragments ... protein drug targets, allowing scientists to ...
Biology Products: